Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004408 | 0.79 | ALDH1A1 (0.60) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL1460717 | 0.79 | ALDH1A1 (0.80) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL4008607 | 0.78 | MAPK1 (0.67) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL6087185 | 0.77 | ESR1 (0.53) | NPC1RAB9ACA1CA2 | |
| SCHEMBL10586698 | 0.77 | MEN1 (0.61) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL2845149 | 0.77 | MEN1 (0.65) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL1460972 | 0.76 | MEN1 (0.55) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL4014193 | 0.75 | MEN1 (0.66) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL1460561 | 0.75 | MEN1 (0.66) | MEN1KMT2AMAPK1ALDH1A1ROCK2 | |
| SCHEMBL5491142 | 0.75 | MEN1 (1.00) | MEN1KMT2AMAPK1ALDH1A1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138418-B2 | For therapy of atherosclerosis and hypercholesterolemia; 5-Pentafluorophenylsulfonamidoindazole for example; increasing LDL receptor gene expression in a cell | AMGEN, INC. (US) | 2006-11-21 | — | — | US | claimed |
| US-6962929-B2 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. (US) | 2005-11-08 | — | — | US | claimed |
| EP-0939627-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2003-08-28 | — | — | US | claimed |
| JP-3421350-B2 | — | — | 2003-06-30 | — | — | JP | claimed |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2002-10-03 | — | — | US | claimed |
| JP-2000515545-A | — | — | 2000-11-21 | — | — | JP | claimed |
| EP-0939627-A4 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2000-10-04 | — | — | EP | claimed |
| US-6121304-A | SUCH AS 1-(PENTAFLUOROPHENYLSULFONYL)INDOLE; USEFUL IN TREATING ATHEROSCLEROSIS AND HYPERCHOLESTEROLERNIA | TULARIK INC (US) | 2000-09-19 | — | — | US | claimed |
| EP-0939627-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-09-08 | — | — | EP | claimed |
| EP-0896533-A4 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 1999-04-28 | — | — | EP | claimed |
| EP-0896533-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-02-17 | — | — | EP | claimed |
| WO-1998005315-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1998-02-12 | — | — | WO | claimed |
| WO-1997030677-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1997-08-28 | — | — | WO | claimed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7138418-B2 | For therapy of atherosclerosis and hypercholesterolemia; 5-Pentafluorophenylsulfonamidoindazole for example; increasing LDL receptor gene expression in a cell | AMGEN, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-0896533-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-02-17 | — | — | EP | disclosed |
| WO-1998005315-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997030677-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | FGFR1, FPR1, FGF1 | MEN1 1013/4885KMT2A 4617/4885MAPK1 163/4885 |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | FFAR1, PCSK9, PFAS | MEN1 502/4885KMT2A 4351/4885MAPK1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.